


## CLAIMS

1. The use of a compound having the general formula Ia



wherein  $R^1$ ,  $R^{1a}$ ,  $R^2$  and  $R^{2a}$  independently are hydrogen, halogen, trifluoromethyl,  $C_{1-6}$ -alkyl,  $C_{1-6}$ -alkoxy, hydroxy,  $NR^7R^8$ , cyano, methylthio or  $-SO_2NR^7R^8$  wherein  $R^7$  and  $R^8$  independently are hydrogen or  $C_{1-6}$ -alkyl; and

Y is  $\underline{N}$ -CH<sub>2</sub>-,  $\underline{CH}$ -CH<sub>2</sub>- or  $\underline{C}$ =CH- wherein only the underscored atom participates in the ring system; or

Y is  $\underline{CH_2N}$ (-)-CH<sub>2</sub>-,  $\underline{CH_2N}$ (-)-CH<sub>2</sub>-,  $\underline{(C=O)N}$ (-)-CH<sub>2</sub>-,  $\underline{CH_2N}$ (-)- $\underline{(C=O)}$ -,  $\underline{CH_2CH}$ (-)-CH<sub>2</sub>-,  $\underline{CH_2CH}$ (-)-CH<sub>2</sub>-,  $\underline{CH_2C}$ (-)=CH-,  $\underline{CH=CH}$ (-)-CH<sub>2</sub>-,  $\underline{OCH}$ (-)-CH<sub>2</sub>-,  $\underline{CH_2CH}$ (-)- $\underline{O}$ -,  $\underline{SCH}$ (-)-CH<sub>2</sub>-,  $\underline{CH_2CH}$ (-)- $\underline{S}$ -, wherein only the underscored atom participates in the ring system; or

Y is  $\underline{N}$ -,  $\underline{CH}$ -,  $\underline{N}$ -(C=O)- or  $\underline{C}$ =C( $R^8$ )-, wherein only the underscored atom participates in the ring system and  $R^8$  is hydrogen or  $C_{1-6}$ -alkyl; or


Y is  $\underline{CH}$ -O- or  $\underline{CH}$ -S(O)<sub>y</sub>, wherein y is 0, 1 or 2, or -N( $R^8$ )- wherein  $R^8$  is hydrogen or  $C_{1-6}$ -alkyl, and wherein only the underscored atom participates in the ring system; and

X is completion of an optional bond, ortho-phenylene, -O-, -S-, -C( $R^7R^8$ )-, -CH<sub>2</sub>CH<sub>2</sub>-, -CH=CH-CH<sub>2</sub>-, -CH<sub>2</sub>-CH=CH-, -CH<sub>2</sub>-(C=O)-, -(C=O)-CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, -CH=CH-, -N( $R^8$ )-(C=O)-, -(C=O)-N( $R^8$ )-, -O-CH<sub>2</sub>-, -CH<sub>2</sub>-O-, -OCH<sub>2</sub>O-, -CH<sub>2</sub>OCH<sub>2</sub>-, -S-CH<sub>2</sub>-, -CH<sub>2</sub>-S-, -(CH<sub>2</sub>)N( $R^8$ )-, -N( $R^8$ )(CH<sub>2</sub>)-, -N(CH<sub>3</sub>)SO<sub>2</sub>-, -SO<sub>2</sub>N(CH<sub>3</sub>)-, -CH( $R^9$ )CH<sub>2</sub>-, -CH<sub>2</sub>CH( $R^9$ )-, -(C=O)-, -N( $R^8$ )- or -(S=O)- wherein  $R^7$  and  $R^8$  independently are hydrogen or  $C_{1-6}$ -alkyl; and wherein  $R^9$  is  $C_{1-6}$ -alkyl or phenyl; and

p and q independently are 0 or 1; and


r is 0, 1, 2, 3 or 4; and

Z is selected from



- 5 wherein R<sup>6</sup> is OH or C<sub>1-6</sub>-alkoxy; and  
 .... is optionally a single bond or a double bond; or

Z is selected from



10

wherein n is 1 or 2;

R<sup>3</sup> is -(CH<sub>2</sub>)<sub>m</sub>OH or -(CH<sub>2</sub>)<sub>s</sub>COR<sup>4</sup> wherein m is 0, 1, 2, 3, 4, 5 or 6 and s is 0 or 1 and wherein

R<sup>4</sup> is -OH, -NH<sub>2</sub>, -NHOH or C<sub>1-6</sub>-alkoxy; and


R<sup>5</sup> is hydrogen, halogen, trifluoromethyl, hydroxy, C<sub>1-6</sub>-alkyl or C<sub>1-6</sub>-alkoxy; and

- 15 R<sup>10</sup> is hydrogen, C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-alkoxy or phenyl optionally substituted with halogen,  
 trifluoromethyl, hydroxy, C<sub>1-6</sub>-alkyl or C<sub>1-6</sub>-alkoxy; and

R<sup>11</sup> is hydrogen or C<sub>1-6</sub>-alkyl; and

.... is optionally a single bond or a double bond; or

Z is selected from



5

wherein u is 0 or 1;

$R^3$  is  $-(CH_2)_mOH$  or  $-(CH_2)_sCOR^4$  wherein m is 0, 1, 2, 3, 4, 5 or 6 and s is 0 or 1 and wherein


$R^4$  is  $-OH$ ,  $-NH_2$ ,  $-NHOH$  or  $C_{1-6}$ -alkoxy; and

$R^5$  is hydrogen, halogen, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy; and


10  $R^{10a}$  is hydrogen or  $C_{1-6}$ -alkyl; and

A is  $C_{1-6}$ -alkylene,  $C_{2-6}$ -alkenylene or  $C_{2-6}$ -alkynylene; or

Z is selected from



- wherein  $M_1$  and  $M_2$  independently are C or N; and  
 $R^{35}$  is hydrogen,  $C_{1-6}$ -alkyl, phenyl or benzyl; and  
 $R^{33}$  is hydrogen, halogen, trifluoromethyl, nitro or cyano; and  
 5  $R^{34}$  is hydrogen, halogen, trifluoromethyl, nitro, cyano,  $-(CH_2)_wCOR^{31}$ ,  $-(CH_2)_wOH$  or  $-(CH_2)_wSO_2R^{31}$  wherein  $R^{31}$  is hydroxy,  $C_{1-6}$ -alkoxy or  $NHR^{32}$ , wherein  $R^{32}$  is hydrogen or  $C_{1-6}$ -alkyl, and  $w$  is 0, 1 or 2; or  
 $R^{34}$  is selected from



10


; or

Z is

- 15 wherein  $b$  is 0, 1, 2, 3 or 4; and


B is  $-\text{CH}=\text{CR}^{49}-$ ,  $-\text{CR}^{49}=\text{CH}-$ ,  $-\text{C}\equiv\text{C}-$ ,  $-(\text{C}=\text{O})-$ ,  $-(\text{C}=\text{CH}_2)-$ ,  $-(\text{CR}^{49}\text{R}^{40})-$ ,  $-\text{CH}(\text{OR}^{41})-$ ,  $-\text{CH}(\text{NHR}^{41})-$ , phenylene,  $C_{3-7}$ -cycloalkylene or the completion of a bond, wherein  $R^{49}$  and  $R^{40}$  independently are hydrogen,  $C_{1-6}$ -unbranched alkyl,  $C_{3-6}$ -branched alkyl or  $C_{3-7}$ -cycloalkyl and wherein  $R^{41}$  is hydrogen or  $C_{1-6}$ -alkyl; and

- 20 U is




wherein  $R^{42}$  is hydrogen,  $-(CH_2)_cOH$  or  $-(CH_2)_dCOR^{47}$  wherein  $c$  is 0, 1, 2, 3, 4, 5 or 6 and  $d$  is 0 or 1 and wherein  $R^{47}$  is  $-\text{OH}$ ,  $-\text{NHR}^{44}$  or  $C_{1-6}$ -alkoxy wherein  $R^{44}$  is hydrogen or  $C_{1-6}$ -alkyl; and

- $R^{43}$  is cyano,  $-NR^{45}R^{47}$ ,  $-NR^{45}-V$  or  $-(CHR^{48})_e-V$  wherein  $R^{45}$  and  $R^{47}$  independently are hydrogen or  $C_{1-6}$ -alkyl and wherein  $e$  is 0, 1, 2, 3, 4, 5 or 6 and wherein  $R^{48}$  is hydrogen, halogen, cyano, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl,  $C_{1-6}$ -alkoxy,  $-NR^{45}R^{47}$  or  $-COOH$ , and wherein  $V$  is  $C_{3-8}$ -cycloalkyl, aryl or heteroaryl, which rings may optionally be substituted with one or more halogen, cyano, trifluoromethyl, hydroxy, methylthio,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy; or
- 5 U is selected from




- 10 wherein  $g$  is 0, 1 or 2; and

- $R^{11u}$  is hydrogen,  $C_{1-6}$ -alkyl,  $C_{1-6}$ -alkoxy or phenyl optionally substituted with halogen, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy; and
- $R^{12u}$  is  $-(CH_2)_hOH$  or  $-(CH_2)_jCOR^{17u}$  wherein  $h$  is 0, 1, 2, 3, 4, 5 or 6 and  $j$  is 0 or 1 and wherein  $R^{17u}$  is  $-OH$ ,  $-NHR^{20u}$  or  $C_{1-6}$ -alkoxy wherein  $R^{20u}$  is hydrogen or  $C_{1-6}$ -alkyl; and
- 5  $R^{13u}$  is hydrogen, halogen, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy; and
- $R^{14u}$  is hydrogen or  $C_{1-6}$ -alkyl; and
- $C$  is  $C_{1-6}$ -alkylene,  $C_{2-6}$ -alkenylene or  $C_{2-6}$ -alkynylene; and
- $\dots$  is optionally a single bond or a double bond; and
- $R^{18u}$  is selected from



10

- wherein  $M_1$  and  $M_2$  independently are C or N; and
- $R^{19u}$  is hydrogen,  $C_{1-6}$ -alkyl, phenyl or benzyl; and
- $R^{15u}$  is hydrogen, halogen, trifluoromethyl, nitro or cyano; and
- $R^{16u}$  is hydrogen, halogen, trifluoromethyl, nitro, cyano,  $-(CH_2)_kCOR^{17u}$ ,  $-(CH_2)_kOH$  or  $-(CH_2)_kSO_2R^{17u}$  wherein  $k$  is 0, 1 or 2; or
- 15  $R^{16u}$  is selected from




; or

20


Z is selected from

65



wherein  $R^{53}$  is  $-(CH_2)_{pp}COOH$  wherein  $pp$  is 2, 3, 4, 5 or 6; or

5 Z is



wherein  $tt$  and  $t$  independently are 0, 1 or 2; and


$R^{63}$  is H,  $C_{1-6}$ -alkyl or optionally substituted benzyl;

10  $R^{64}$  and  $R^{65}$  independently are H,  $C_{1-8}$ -alkyl,  $C_{3-7}$ -cycloalkyl, phenyl, thienyl, benzyl, or  $R^{64}$  and  $R^{65}$  together with the C-atom they are attached to form a 3 - 8 membered carbocyclic ring;

and

$R^{66}$  is H or  $C_{1-6}$ -alkyl; or

15 Z is selected from




wherein D is  $-CH_2-$ ,  $-O-$ ,  $-S-$  or  $-N(R^7)-$  wherein  $R^7$  is hydrogen or  $C_{1-6}$ -alkyl; and

$R^{3m}$  is  $-(CH_2)_{mm}OH$  or  $-(CH_2)_{mp}COR^4$  wherein  $mm$  and  $mp$  are 1, 2, 3 or 4 and  $R^4$  is OH,


20  $NH_2$ ,  $NHOH$  or  $C_{1-6}$ -alkoxy; or

having the general formula Ib




(lb)

- 5 wherein R<sup>1b</sup> and R<sup>2b</sup> independently are hydrogen, halogen, trifluoromethyl, hydroxy, C<sub>1-6</sub>-alkyl or C<sub>1-6</sub>-alkoxy; and R<sup>3b</sup> is hydrogen or C<sub>1-3</sub>-alkyl; and A<sub>b</sub> is C<sub>1-3</sub>-alkylene; and Y<sub>b</sub> is >CH-CH<sub>2</sub>-, >C=CH-, >CH-O-, >C=N-, >N-CH<sub>2</sub>- wherein only the underscored atom  
10 participates in the ring system; and Z<sub>b</sub> is selected from





67



wherein nb is 1 or 2; and

$R^{11b}$  is hydrogen or  $C_{1-6}$ -alkyl; and

- 5  $R^{12b}$  is hydrogen,  $C_{1-6}$ -alkyl,  $C_{1-6}$ -alkoxy or phenyl optionally substituted with halogen, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy; and

$R^{13b}$  is hydrogen, halogen, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy; and


$R^{14b}$  is  $-(CH_2)_{mb}OH$  or  $-(CH_2)_{tb}COR^{15b}$  wherein mb is 0, 1, 2, 3, 4, 5 or 6 and tb is 0 or 1 and wherein  $R^{15b}$  is  $-OH$ ,  $NH_2$ ,  $-NHOH$  or  $C_{1-6}$ -alkoxy; and

- 10  $R^{16b}$  is  $C_{1-6}$ -alkyl or  $-B_b-COR^{15b}$ , wherein  $B_b$  is  $C_{1-6}$ -alkylene,  $C_{2-6}$ -alkenylene or  $C_{2-6}$ -alkynylene and  $R^{15b}$  is the same as above; and

$\dots$  is optionally a single bond or a double bond; or

having the general formula Ic

15



(Ic)

wherein  $R^{1c}$  and  $R^{2c}$  independently are hydrogen, halogen, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy;


$X_c$  is ortho-phenylene, -O-, -S-, -C( $R^{6c}R^{7c}$ )-, -CH<sub>2</sub>CH<sub>2</sub>-, -CH=CH-CH<sub>2</sub>-, -CH<sub>2</sub>-CH=CH-, -CH<sub>2</sub>-(C=O)-, -(C=O)-CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, -CH=CH-, -N( $R^{8c}$ )-(C=O)-, -(C=O)-N( $R^{8c}$ )-, -O-CH<sub>2</sub>-, -CH<sub>2</sub>-O-, -OCH<sub>2</sub>O-, -S-CH<sub>2</sub>-, -CH<sub>2</sub>-S-, -(CH<sub>2</sub>)N( $R^{8c}$ )-, -N( $R^{8c}$ )(CH<sub>2</sub>)-, -N(CH<sub>3</sub>)SO<sub>2</sub>-, -SO<sub>2</sub>N(CH<sub>3</sub>)-, -CH( $R^{10c}$ )CH<sub>2</sub>-, -CH<sub>2</sub>CH( $R^{10c}$ )-, -(C=O)-, -N( $R^{9c}$ )- or -(S=O)- wherein  $R^{6c}$ ,  $R^{7c}$ ,  $R^{8c}$  and  $R^{9c}$  independently are hydrogen or  $C_{1-6}$ -alkyl, and wherein  $R^{10c}$  is  $C_{1-6}$ -alkyl or phenyl;

$Y_c$  is C or N;

.... is optionally a single bond or a double bond, and ... is a single bond when  $Y_c$  is N;


mc is 1, 2, 3, 4, 5 or 6; and

$Z_c$  is -COOR<sup>3c</sup> or



wherein  $R^{3c}$  is H or  $C_{1-6}$ -alkyl; or

having the general formula Id






wherein  $R^{1d}$  and  $R^{2d}$  independently are hydrogen, halogen, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy; and

$X_d$  is -O-, -S- or -S(=O)-; and

rd is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; and

$Z_d$  is selected from

69



wherein  $R^{3d}$  is  $-(CH_2)_{md}OH$  or  $-(CH_2)_{pd}COR^{4d}$  wherein  $md$  and  $pd$  independently are 0, 1, 2, 3 or 4 and  $R^{4d}$  is OH,  $NH_2$ ,  $NHOH$  or  $C_{1-6}$ -alkoxy; or

a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for the treatment of an indication related to angiogenesis.

2. The use according to claim 1 wherein angiogenesis is related to cancer.

3. The use according to claim 1 wherein angiogenesis is related to ocular neovascularization.

4. The use according to anyone of the claims 1-3 wherein in formula Ia  $R^1$ ,  $R^{1a}$ ,  $R^2$  and  $R^{2a}$  independently are hydrogen, halogen, trifluoromethyl,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy; and



$Y$  is  $>\underline{N}-CH_2-$ ,  $>\underline{CH}-CH_2-$  or  $>\underline{C}=CH-$  wherein only the underscored atom participates in the ring system; and

$X$  is  $-O-$ ,  $-S-$ ,  $-C(R^7R^8)-$ ,  $-CH_2CH_2-$ ,  $-\underline{CH}=CH-CH_2-$ ,  $-CH_2-CH=CH-$ ,  $-CH_2CH_2CH_2-$ ,  $-CH=CH-$ ,  $-N(R^8)-(C=O)-$ ,  $-O-CH_2-$ ,  $-(C=O)-$  or  $-(S=O)-$  wherein  $R^7$  and  $R^8$  independently are hydrogen or  $C_{1-6}$ -alkyl; and

$p$  and  $q$  are 0, and

$r$  is 1, 2 or 3; and

$Z$  is selected from



wherein  $R^6$  is OH or  $C_{1-6}$ -alkoxy; and

$\dots$  is optionally a single bond or a double bond; or

a pharmaceutically acceptable salt thereof.

5. The use according to anyone of the claims 1- 4 wherein the compound is selected from the following:

- (R)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;
- 5 (S)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;
- 10 1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylic acid;
- (R)-1-(3-(Fluoren-9-ylidene)-1-propyl)-3-piperidinecarboxylic acid;
- 15 1-(3-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;
- 1-(3-(Thioxanthen-9-ylidene)-1-propyl)-3-piperidinecarboxylic acid;
- (R)-1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;
- 20 (R)-1-(4-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-butyl)-3-piperidinecarboxylic acid;
- (R)-1-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)ethyl)-3-piperidinecarboxylic acid;
- 25 (R)-1-(3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;
- (R)-1-(3-(10H-Phenothiazin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;
- 30 (R)-1-(3-(10H-Phenoxazin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;
- (S)-1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;
- 1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-3-pyrrolidinacetic acid;
- 35

- (R)-1-(3-(3-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;
- 5 (R)-1-(3-(2-Trifluoromethyl-10H-phenothiazin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;
- (R)-1-(3-(5-Oxo-10H-phenothiazin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;
- 10 (R)-1-(3-(11H-10-Oxa-5-aza-5H-dibenzo[a,d]cyclohepten-5-yl)-1-propyl)-3-piperidinecarboxylic acid;
- 1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylic acid;
- (R)-1-(3-(6,7-Dihydro-5H-dibenzo[b,g]azocin-12-yl)-1-propyl)-3-piperidinecarboxylic acid;
- 15 (R)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-1-propyl)-3-piperidinecarboxylic acid;
- (R)-1-(3-Methoxy-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;
- 20 (R)-1-(3-(10-Methyl-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;
- 25 (R)-1-(3-(9(H)-Oxo-10H-acridin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;
- (R)-1-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-ethyl)-3-piperidinecarboxylic acid hydrochloride;
- 30 (R)-1-(2-(6,11-Dihydrodibenz[b,e]oxepin-11-ylidene)-1-ethyl)-3-piperidinecarboxylic acid hydrochloride;
- (R)-1-(3-(2-Chloro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;
- 35

(R)-1-(3-(2-Bromo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

5 (R)-1-(3-(2-Fluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

(R)-1-(3-(2-Iodo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

10 (Z)-(R)-1-(3-(2-Iodo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

15 (E)-(R)-1-(3-(2-Iodo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

(R)-1-(3-(2-Methoxy-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride,

or a pharmaceutically acceptable salt thereof,

20 6. The use according to anyone of the claims 1-3 wherein in formula Ia  $R^1$ ,  $R^{1a}$ ,  $R^2$  and  $R^{2a}$  independently are hydrogen, halogen, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy; and


Y is  $-\underline{CH_2N}(-)CH_2-$ ,  $-CH_2\underline{N}(-)CH_2-$ ,  $-(\underline{C=O})N(-)CH_2-$ ,  $-CH_2N(-)(\underline{C=O})-$ ,  $-\underline{CH_2CH}(-)CH_2-$ ,  $-CH_2CH(-)\underline{CH_2}-$ ,  $-\underline{CH_2C}(-)=CH-$ ,  $-CH=\underline{C}(-)CH_2-$ ,  $-\underline{OCH}(-)CH_2-$ ,  $-CH_2CH(-)\underline{O}-$ ,  $-\underline{SCH}(-)CH_2-$ ,  $-CH_2CH(-)\underline{S}-$ , wherein only the underscored atom participates in the ring system; and

25 X is  $-O-$ ,  $-S-$ ,  $-C(R^7R^8)-$ ,  $-CH_2CH_2-$ ,  $-CH=CH-CH_2-$ ,  $-CH_2-CH=CH-$ ,  $-CH_2-(C=O)-$ ,  $-(C=O)-CH_2-$ ,  $-CH_2CH_2CH_2-$ ,  $-CH=CH-$ ,  $-N(R^8)-(C=O)-$ ,  $-(C=O)-N(R^8)-$ ,  $-O-CH_2-$ ,  $-CH_2-O-$ ,  $-S-CH_2-$ ,  $-CH_2-S-$ ,  $-N(R^8)-$ ,  $-(C=O)-$  or  $-(S=O)-$  wherein  $R^7$  and  $R^8$  independently are hydrogen or  $C_{1-6}$ -alkyl; and

30 p and q independently are 0 or 1; and

r is 1, 2 or 3; and

Z is selected from



wherein  $\text{R}^6$  is OH or  $\text{C}_{1-6}$ -alkoxy; and

... is optionally a single bond or a double bond; or  
a pharmaceutically acceptable salt thereof.

5


7. The use according to anyone of the claims 1-3 and 6 wherein the compound is selected from the following:

- (R)-1-(3-(6,11-Dioxo-6,11-dihydro-5H-dibenz[b,e]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;
- 10 (R)-1-(3-(6,11-Dihydro-5H-dibenz[b,e]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;
- (R)-1-(3-(5,11-Dihydro-10H-dibenzo[b,e][1,4]diazepin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;
- 15 (R)-1-(3-(11H-Dibenzo[b,f][1,4]thiazepin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;
- (R)-1-(3-(11H-Dibenzo[b,f][1,4]oxazepin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;
- 20 (R)-1-(3-(11H-Dibenzo[b,f][1,4]oxathiepin-11-yl)-1-propyl)-3-piperidinecarboxylic acid;
- (R)-1-(3-(11H-Dibenzo[b,e][1,4]dithiepin-11-yl)-1-propyl)-3-piperidinecarboxylic acid;
- 25 (R)-1-(3-(11H-Dibenzo[b,e][1,4]oxathiepin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;
- (R)-1-(3-(11,12-Dihydro-10H-dibenz[b,g][1,5]oxazocin-11-yl)-1-propyl)-3-piperidinecarboxylic acid;
- 30 (R)-1-(3-(11,12-Dihydro-10H-dibenzo[b,g][1,5]thiazocin-11-yl)-1-propyl)-3-piperidinecarboxylic acid;

- 1-(3-(11,12-Dihydro-6H-dibenz[b,f]azocin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;
- 5 1-(3-(11,12-Dihydro-5H-dibenzo[a,e]cycloocten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;
- 1-(3-(6-Oxo-11,12-dihydro-5H-dibenz[b,f]azocin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;
- 10 1-(3-(7,12-Dihydro-6H-dibenzo[a,d]cycloocten-6-ylidene)-1-propyl)-3-piperidinecarboxylic acid;
- 1-(3-(5-Methyl-5,11-dihydro-dibenz[b,f]azepin-10-ylidene)-1-propyl)-3-piperidinecarboxylic acid;
- 15 1-(3-(6-Oxo-5,11-dihydro-5H-dibenz[b,e]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;
- (R)-1-(3-(11-Oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;
- 20 (R)-1-(3-(6-Oxo-11,12-dihydro-5H-dibenz[b,f]azocin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;
- (R)-1-(3-(10,11-Dihydro-dibenz[b,f][1,4]oxazepin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;
- 25 (R)-1-(3-(5,6,11,12-Tetrahydro-dibenz[b,f]azocin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;
- (R)-1-(3-(11-Oxo-6,11-dihydro-5H-dibenz[b,e]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;
- 30 (R)-1-(3-(5-Methyl-dibenz[b,f]azepin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;
- (R)-1-(3-(6,7-Dihydro-5H-dibenz[b,g][1,5]oxazocin-6-yl)-1-propyl)-3-piperidinecarboxylic acid;
- (R)-1-(3-(11,12-Dihydro-dibenz[a,e]cycloocten-5-yl)-1-propyl)-3-piperidinecarboxylic acid,
- 35 or a pharmaceutically acceptable salt thereof.



8. The use according to anyone of the claims 1-3 wherein in formula Ia
- $R^1$ ,  $R^{1a}$ ,  $R^2$  and  $R^{2a}$  independently are hydrogen, halogen, trifluoromethyl,  $NR^7R^8$ , hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy wherein  $R^7$  and  $R^8$  independently are hydrogen or  $C_{1-6}$ -alkyl; and
- 5 Y is  $\text{>}\underline{N}\text{-CH}_2\text{-}$ ,  $\text{>}\underline{CH}\text{-CH}_2\text{-}$  or  $\text{>}\underline{C}\text{=CH-}$  wherein only the underscored atom participates in the ring system; and
- X is  $\text{-O-}$ ,  $\text{-S-}$ ,  $\text{-C(R}^7\text{R}^8\text{)-}$ ,  $\text{-CH}_2\text{CH}_2\text{-}$ ,  $\text{-CH=CH-CH}_2\text{-}$ ,  $\text{-CH}_2\text{-CH=CH-}$ ,  $\text{-CH}_2\text{-(C=O)-}$ ,  $\text{-(C=O)-CH}_2\text{-}$ ,  $\text{-CH}_2\text{CH}_2\text{CH}_2\text{-}$ ,  $\text{-CH=CH-}$ ,  $\text{-N(R}^8\text{)-(C=O)-}$ ,  $\text{-(C=O)-N(R}^8\text{)-}$ ,  $\text{-O-CH}_2\text{-}$ ,  $\text{-CH}_2\text{-O-}$ ,  $\text{-S-CH}_2\text{-}$ ,  $\text{-CH}_2\text{-S-}$ ,  $\text{-N(R}^8\text{)-}$ ,  $\text{-(C=O)-}$  or  $\text{-(S=O)-}$  wherein  $R^7$  and  $R^8$  independently are hydrogen or  $C_{1-6}$ -alkyl; and
- 10 p and q are 0; and
- r is 1, 2 or 3; and
- Z is selected from



- wherein n is 1 or 2; and
- 15  $R^3$  is  $\text{-(CH}_2\text{)}_m\text{OH}$  or  $\text{-(CH}_2\text{)}_s\text{COR}^4$  wherein m is 0, 1, 2, 3, 4, 5 or 6 and s is 0 or 1 and wherein  $R^4$  is  $\text{-OH}$ ,  $\text{-NH}_2$ ,  $\text{-NHOH}$  or  $C_{1-6}$ -alkoxy; and
- $R^5$  is hydrogen, halogen, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy; and
- $R^{10}$  is hydrogen,  $C_{1-6}$ -alkyl,  $C_{1-6}$ -alkoxy or phenyl optionally substituted with halogen, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy; and
- 20  $R^{11}$  is hydrogen or  $C_{1-6}$ -alkyl; and
- ... is optionally a single bond or a double bond; or

a pharmaceutically acceptable salt thereof.

9. The use according to anyone of the claims 1-3 and 8 wherein the compound is selected from the following:

5

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-3-piperidine-carboxamide;

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidinecarboxylic acid;

10

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-2-piperidinecarboxylic acid;

(1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-3-piperidinyl)methanol;

15

4-(4-Chlorophenyl)-1-(3-(10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidinol;

4-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-2-piperazinecarboxylic acid;

(2S,4R)-1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-hydroxy-2-pyrrolidinecarboxylic acid;

20

4-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-2-morpholinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-2-aziridinecarboxylic acid;

25

2-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-1,2,3,4-tetrahydro-4-isoquinolinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-methyl-[1,4]-diazepane-6-carboxylic acid;

30

2-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid;


35

1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid hydroxamide;

- (4-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)piperazin-1-yl)acetic acid;
- 1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidinecarboxylic acid;
- 5 4-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-2-piperazinecarboxylic acid;
- 1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidineacetic acid;
- 1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-piperidinecarboxylic  
10 acid;
- (R)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-  
piperidinecarboxamide;
- 15 (R)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-2-  
pyrrolidinecarboxylic acid;
- (S)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-2-  
pyrrolidinecarboxylic acid;
- 20 1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-2-piperidinecarboxylic  
acid;
- 1-(3-(10H-Phenoxazin-10-yl)-1-propyl)-4-piperidinecarboxylic acid;
- 25 1-(3-(3-Chloro-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidinecarboxylic  
acid;
- 1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-3-piperidineacetic acid;
- 30 1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-2-methyl-3-piperidinecarboxylic  
acid;
- 1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-3-quinuclidiniumcarboxylate;
- 35

- 1-(3-(2,8-Dibromo-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidinecarboxylic acid;
- 5 1-(3-(3,7-Dichloro-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidinecarboxylic acid;
- 1-(3-(3-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-piperidinecarboxylic acid;
- 10 1-(3-(3,7-Dimethyl-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidinecarboxylic acid;
- 1-(3-(3-Dimethylamino-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-4-piperidinecarboxylic acid;
- 15 (R)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-2-piperidinecarboxylic acid;
- (S)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-2-piperidinecarboxylic acid;
- 20 1-(2-(6,11-Dihydrodibenzo[b,e]thiepin-11-ylidene)-1-ethyl)-3-piperidinecarboxylic acid;
- 1-(2-(6,11-Dihydrodibenzo[b,e]thiepin-11-ylidene)-1-ethyl)-4-piperidinecarboxylic acid;
- 25 1-(2-(2-Chloro-6,11-dihydrodibenzo[b,e]thiepin-11-ylidene)-1-ethyl)-3-piperidinecarboxylic acid;
- 1-(2-(2-Chloro-6,11-dihydrodibenzo[b,e]thiepin-11-ylidene)-1-ethyl)-4-piperidinecarboxylic acid;
- 30 (R)-1-(2-(6,11-Dihydrodibenzo[b,e]thiepin-11-ylidene)-1-ethyl)-3-piperidinecarboxylic acid;
- 1-(3-(2-Bromo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-pyrrolidineacetic acid;
- 35

- 1-(3-(3-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-pyrrolidineacetic acid;
- 1-(3-(6,11-Dihydro-dibenz[b,e]thiepin-11-ylidene)-1-propyl)-4-piperidinecarboxylic acid;
- 1-(3-(2-Fluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-piperidinecarboxylic acid;
- 1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-2-piperidineacetic acid;
- 1-(3-(Phenothiazin-10-yl)-1-propyl)-4-piperidinecarboxylic acid;
- (R)-1-(2-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-ethyl)-2-piperidinecarboxylic acid;
- 1-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-ethyl)-4-piperidinecarboxylic acid;
- 1-(2-(6,11-Dihydrodibenzo[b,e]oxepin-11-ylidene)-1-ethyl)-4-piperidinecarboxylic acid,
- or a pharmaceutically acceptable salt thereof.
10. The use according to anyone of the claims 1-3 wherein in formula Ia
- $R^1$ ,  $R^{1a}$ ,  $R^2$  and  $R^{2a}$  independently are hydrogen, halogen, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy; and
- Y is  $\text{>N-CH}_2\text{-}$ ,  $\text{>CH-CH}_2\text{-}$  or  $\text{>C=CH-}$  wherein only the underscored atom participates in the ring system; and
- X is ortho-phenylene,  $\text{-CH}_2\text{-(C=O)-}$ ,  $\text{-(C=O)-CH}_2\text{-}$ ,  $\text{-S-CH}_2\text{-}$ ,  $\text{-CH}_2\text{-S-}$ ,  $\text{-(CH}_2\text{)N(R}^8\text{)-}$ ,  $\text{-N(R}^8\text{)(CH}_2\text{)-}$ ,  $\text{-N(CH}_3\text{)SO}_2\text{-}$ ,  $\text{-SO}_2\text{N(CH}_3\text{)-}$ ,  $\text{-CH(R}^9\text{)CH}_2\text{-}$  or  $\text{-CH}_2\text{CH(R}^9\text{)-}$  wherein  $R^8$  is hydrogen or  $C_{1-6}$ -alkyl and  $R^9$  is  $C_{1-6}$ -alkyl or phenyl; and
- p and q are 0; and
- r is 1, 2 or 3; and
- Z is selected from



wherein  $R^6$  is OH or  $C_{1-6}$ -alkoxy; and

... is optionally a single bond or a double bond; or  
a pharmaceutically acceptable salt thereof.

5

11. The use according to anyone of the claims 1-3 and 10 wherein the compound is selected from the following:

10

1-(3-(9H-Tribenz[b,d,f]azepin-9-yl)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(Tribenzo[a,c,e]cyclohepten-9-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(5-Methyl-5,6-dihydrodibenz[b,e]azepin-11-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

15

1-(3-(6-Methyl-6H-dibenzo[c,f][1,2]thiazepin-5,5-dioxide-11-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(10-Methyl-10,11-dihydro-5H-dibenzo[b,e]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

20

1-(3-(10-Phenyl-10,11-dihydro-5H-dibenzo[b,e]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(6,11-Dihydro-11H-dibenzo[b,e][1,4]thiazepin-11-yl)-1-propyl)-3-piperidinecarboxylic acid;

25

1-(3-(10-Methyl-10,11-dihydro-dibenzo[b,e][1,4]diazepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

30

(R)-1-(3-(10-Oxo-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;





(R)-1-(3-(6-Methyl-6,11-dihydro-dibenzo[c,f][1,2,5]thiadiazepin-5,5-dioxide-11-yl)-1-propyl)-3-piperidinecarboxylic acid;

5 (R)-1-(3-(5-Methyl-5,6-dihydrodibenz[b,e]azepin-11-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(9H-Tribenzo[a,c,e]cyclohepten-9-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

10 (R)-1-(3-(9H-Tribenzo[b,d,f]azepine-9-yl)propyl)-3-piperidinecarboxylic acid,  
or a pharmaceutically acceptable salt thereof.

12. The use according to anyone of the claims 1-3 wherein in formula Ia  
 15  $R^1$ ,  $R^{1a}$ ,  $R^2$  and  $R^{2a}$  independently are hydrogen, halogen, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy; and  
 Y is  $\text{>N-CH}_2\text{-}$ ,  $\text{>CH-CH}_2\text{-}$  or  $\text{>C=CH-}$  wherein only the underscored atom participates in the ring system; and  
 X is  $\text{-O-}$ ,  $\text{-S-}$ ,  $\text{-C(R}^7\text{R}^8\text{)-}$ ,  $\text{-CH}_2\text{CH}_2\text{-}$ ,  $\text{-CH=CH-CH}_2\text{-}$ ,  $\text{-CH}_2\text{-CH=CH-}$ ,  $\text{-CH}_2\text{-(C=O)-}$ ,  $\text{-(C=O)-CH}_2\text{-}$ ,  $\text{-CH}_2\text{CH}_2\text{CH}_2\text{-}$ ,  $\text{-CH=CH-}$ ,  $\text{-N(R}^8\text{)-(C=O)-}$ ,  $\text{-(C=O)-N(R}^8\text{)-}$ ,  $\text{-O-CH}_2\text{-}$ ,  $\text{-CH}_2\text{-O-}$ ,  $\text{-S-CH}_2\text{-}$ ,  $\text{-CH}_2\text{-S-}$ ,  $\text{-N(R}^8\text{)-}$ ,  $\text{-(C=O)-}$  or  $\text{-(S=O)-}$  wherein  $R^7$  and  $R^8$  independently are hydrogen or  $C_{1-6}$ -alkyl; and  
 20 p and q are 0; and  
 r is 1, 2 or 3; and  
 Z is selected from



wherein u is 0 or 1;

$R^3$  is  $-(CH_2)_mOH$  or  $-(CH_2)_sCOR^4$  wherein m is 0, 1, 2, 3, 4, 5 or 6 and s is 0 or 1 and wherein

$R^4$  is -OH, -NH<sub>2</sub>, -NHOH or C<sub>1-6</sub>-alkoxy; and

5  $R^5$  is hydrogen, halogen, trifluoromethyl, hydroxy, C<sub>1-6</sub>-alkyl or C<sub>1-6</sub>-alkoxy; and

$R^{10a}$  is hydrogen or C<sub>1-6</sub>-alkyl; and

A is C<sub>1-6</sub>-alkylene, C<sub>2-6</sub>-alkenylene or C<sub>2-6</sub>-alkynylene; or

a pharmaceutically acceptable salt thereof.

10 13. The use according to anyone of the claims 1-3 and 12 wherein the compound is selected from the following:

3-(N-Methyl-N-(3-(10,11-dihydrodibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)amino)propionic acid;

15 4-(N-Methyl-N-(3-(10,11-dihydrodibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)amino)butyric acid;

3-((3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)amino)propionic acid;

20 2-(N(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-N-methyl-amino)succinic acid;

2-((3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)amino)benzoic acid;

25 2-(N-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-N-methylamino)nicotinic acid;

2-((N-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-N-methylamino)methyl)benzoic acid;

30 2-((N-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-N-methylamino)-1-cyclohexanecarboxylic acid;

2-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propylamino)pyridin-3-ol;

35 3-((3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)amino)benzoic acid;



2-((3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)amino)benzoic acid;

2-(N-(3-(3-Chloro-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)amino)benzoic acid;

- 5 5-Bromo-2-(N-(3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)amino)benzoic acid,

or a pharmaceutically acceptable salt thereof.

- 10 14. The use according to anyone of the claims 1-3 wherein in formula Ia  $R^1$ ,  $R^{1a}$ ,  $R^2$  and  $R^{2a}$  independently are hydrogen, halogen, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy;


Y is  $>\underline{N}$ -CH<sub>2</sub>-,  $>\underline{CH}$ -CH<sub>2</sub>-,  $>\underline{C}$ =CH- or  $>\underline{CH}$ -O- wherein only the underscored atom participates in the ring system; and

- 15 X is ortho-phenylene, -O-, -S-, -C( $R^7$  $R^8$ )-, -CH<sub>2</sub>CH<sub>2</sub>-, -CH=CH-CH<sub>2</sub>-, -CH<sub>2</sub>-CH=CH-, -CH<sub>2</sub>-(C=O)-, -(C=O)-CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, -CH=CH-, -N( $R^8$ )-(C=O)-, -(C=O)-N( $R^8$ )-, -O-CH<sub>2</sub>-, -CH<sub>2</sub>-O-, -OCH<sub>2</sub>O-, -S-CH<sub>2</sub>-, -CH<sub>2</sub>-S-, -(CH<sub>2</sub>)N( $R^8$ )-, -N( $R^8$ )(CH<sub>2</sub>)-, -N(CH<sub>3</sub>)SO<sub>2</sub>-, -SO<sub>2</sub>N(CH<sub>3</sub>)-, -CH( $R^9$ )CH<sub>2</sub>-, -CH<sub>2</sub>CH( $R^9$ )-, -(C=O)-, -N( $R^8$ )- or -(S=O)- wherein  $R^7$  and  $R^8$  independently are hydrogen or  $C_{1-6}$ -alkyl; and wherein  $R^9$  is  $C_{1-6}$ -alkyl or phenyl; and

- 20 p and q are 0; and

r is 1, 2 or 3; and

Z is selected from



- 25 wherein  $M_1$  and  $M_2$  independently are C or N; and


$R^{35}$  is hydrogen,  $C_{1-6}$ -alkyl, phenyl or benzyl; and

$R^{33}$  is hydrogen, halogen, trifluoromethyl, nitro or cyano; and

$R^{34}$  is hydrogen, halogen, trifluoromethyl, nitro, cyano,  $-(CH_2)_wCOR^{31}$ ,  $-(CH_2)_wOH$  or  $-(CH_2)_wSO_2R^{31}$  wherein  $R^{31}$  is hydroxy,  $C_{1-6}$ -alkoxy or  $NHR^{32}$ , wherein  $R^{32}$  is hydrogen or  $C_{1-6}$ -

5 alkyl, and w is 0, 1 or 2; or

$R^{34}$  is selected from



or a pharmaceutically acceptable salt thereof.

10

15. The use according to anyone of the claims 1-3 and 14 wherein the compound is selected from the following:

15

2-(4-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)piperazin-1-yl)-3-pyridinecarboxylic acid;

2-(4-(3-(2,10-Dichloro-12H-dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-piperazin-1-yl)-3-pyridinecarboxylic acid;

20

2-(4-(3-(12H-Dibenzo[d,g][1,3,6]dioxazocin-12-yl)-1-propyl)piperazin-1-yl)-3-pyridinecarboxylic acid;

2-(4-(3-(2-Chloro-12H-dibenzo[d,g][1,3,6]dioxazocin-12-yl)-1-propyl)-piperazin-1-yl)-3-pyridinecarboxylic acid;

25

1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-(2-pyridyl)piperazine;

- 2-(4-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-propyl)-1-piperazinyl)-3-pyridine-carboxylic acid;
- 5 2-(4-(2-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-ethyl)-1-piperazinyl)-3-pyridinecarboxylic acid;
- 6-(4-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-1-piperazinyl)-2-pyridinecarboxylic acid;
- 10 2-(4-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-1-piperazinyl)-3-pyridinecarboxylic acid;
- 2-(4-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-1-piperazinyl)-5-pyridinecarboxylic acid;
- 15 2-(4-(3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-1-piperazinyl)-3-pyridinecarboxylic acid;
- 1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-(2-nitrophenyl)-piperazine;
- 20 2-(4-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-1-piperazinyl)-benzonitrile;
- 25 2-(4-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-1-piperazinyl)-benzoic acid;
- 1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-(3-trifluoromethyl-2-pyridyl)piperazine;
- 30 2-(4-(2-(6,11-Dihydro-dibenzo[b,e]thiepin-11-ylidene)ethyl)piperazin-1-yl)-3-pyridinecarboxylic acid;
- 2-(4-(3-(6,11-Dihydrodibenzo[b,e]thiepin-11-ylidene)-1-propyl)-1-piperazinyl)-3-pyridinecarboxylic acid;
- 35

2-(4-(2-(6,11-Dihydrodibenzo[b,e]thiepin-11-yloxy)ethyl)-1-piperazinyl)-3-pyridinecarboxylic acid;


5 6-(4-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperazin-1-yl)-2-pyridinecarboxylic acid;

2-(4-(3-(3-Methyl-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-1-piperazinyl)-3-pyridinecarboxylic acid;

10 6-(4-(3-(Dibenzo[d,g][1,3,6]dioxazocin-12-yl)-1-propyl)-piperazin-1-yl)-pyridine-2-carboxylic acid,

or a pharmaceutically acceptable salt thereof.

15 16. The use according to anyone of the claims 1-3 wherein in formula Ia  
 $R^1$ ,  $R^{1a}$ ,  $R^2$  and  $R^{2a}$  independently are hydrogen, halogen, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy; and  
 Y is  $>\underline{N}$ -,  $>\underline{CH}$ -,  $>\underline{N}-(C=O)$ - or  $>\underline{C}=C(R^8)$ -, wherein only the underscored atom participates in the ring system and  $R^8$  is hydrogen or  $C_{1-6}$ -alkyl; and  
 20 X is ortho-phenylene, -O-, -S-,  $-C(R^7)(R^8)$ -,  $-CH_2CH_2$ -,  $-CH=CH-CH_2$ -,  $-CH_2-CH=CH$ -,  $-CH_2-(C=O)$ -,  $-(C=O)-CH_2$ -,  $-CH_2CH_2CH_2$ -,  $-CH=CH$ -,  $-N(R^8)-(C=O)$ -,  $-(C=O)-N(R^8)$ -,  $-O-CH_2$ -,  $-CH_2-O$ -,  $-OCH_2O$ -,  $-CH_2OCH_2$ -,  $-S-CH_2$ -,  $-CH_2-S$ -,  $-(CH_2)N(R^8)$ -,  $-N(R^8)(CH_2)$ -,  $-N(CH_3)SO_2$ -,  $-SO_2N(CH_3)$ -,  $-CH(R^9)CH_2$ -,  $-CH_2CH(R^9)$ -,  $-(C=O)$ -,  $-N(R^8)$ - or  $-(S=O)$ - wherein  $R^7$  and  $R^8$  independently are hydrogen or  $C_{1-6}$ -alkyl; and wherein  $R^9$  is  $C_{1-6}$ -alkyl or phenyl;  
 25 and p and q are 0; and  
 r is 0, 1, 2, 3 or 4; and  
 Z is



wherein b is 0, 1, 2, 3 or 4; and

30 B is  $-CH=CR^{49}$ -,  $-CR^{49}=CH$ -,  $-C\equiv C$ -,  $-(C=O)$ -,  $-(C=CH_2)$ -,  $-(CR^{49}R^{40})$ -,  $-CH(OR^{41})$ -,  $-CH(NHR^{41})$ -, phenylene,  $C_{3-7}$ -cycloalkylene or the completion of a bond, wherein  $R^{49}$  and  $R^{40}$  independently are hydrogen,  $C_{1-6}$ -unbranched alkyl,  $C_{3-6}$ -branched alkyl or  $C_{3-7}$ -cycloalkyl and wherein  $R^{41}$  is hydrogen or  $C_{1-6}$ -alkyl; and  
 U is selected from



R<sup>11u</sup> is hydrogen, C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-alkoxy or phenyl optionally substituted with halogen,

$R^{12u}$  is  $-(CH_2)_hOH$  or  $-(CH_2)_jCOR^{17u}$  wherein  $h$  is 0, 1, 2, 3, 4, 5 or 6 and  $j$  is 0 or 1 and


R<sup>13u</sup> is hydrogen, halogen, trifluoromethyl, hydroxy, C<sub>1-6</sub>-alkyl or C<sub>1-6</sub>-alkoxy; and

C is C<sub>1-6</sub>-alkylene, C<sub>2-6</sub>-alkenylene or C<sub>2-6</sub>-alkynylene; and

10 C is C<sub>1-6</sub>-alkylene, C<sub>2-6</sub>-alkenylene or C<sub>2-6</sub>-alkynylene; and

... is optionally a single bond or a double bond; and

$R^{18u}$  is selected from




wherein  $M_1$  and  $M_2$  independently are C or N; and

5  $R^{19u}$  is hydrogen,  $C_{1-6}$ -alkyl, phenyl or benzyl; and

$R^{15u}$  is hydrogen, halogen, trifluoromethyl, nitro or cyano; and

$R^{16u}$  is hydrogen, halogen, trifluoromethyl, nitro, cyano,  $-(CH_2)_kCOR^{17u}$ ,  $-(CH_2)_kOH$  or  $-(CH_2)_kSO_2R^{17u}$  wherein k is 0, 1 or 2; or

$R^{16u}$  is selected from



or a pharmaceutically acceptable salt thereof.

17. The use according to anyone of the claims 1-3 and 16 wherein the compound is  
15 selected from the following:

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-(3R)-  
piperidinecarboxylic acid;

20 1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-4-  
piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-(2R)-  
piperidinecarboxylic acid;


- 1-(4-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2Z)-butenyl)-(3R)-piperidinecarboxylic acid;
- 5 1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propionyl)-(3R)-piperidine-carboxylic acid;
- 1-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-1-ethyl)-(3R)-piperidine-carboxylic acid;
- 10 1-(4-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2E)-butenyl)-(3R)-piperidinecarboxylic acid;
- 1-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-methyl-1-ethyl)-(3R)-piperidinecarboxylic acid;
- 15 1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-methyl-3-oxopropyl)-(3R)-piperidinecarboxylic acid;
- 20 1-(4-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-butynyl)-(3R)-piperidinecarboxylic acid;
- 1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-methyl-1-propyl)-(3R)-piperidinecarboxylic acid;
- 25 1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-hydroxy-1-propyl)-(3R)-piperidinecarboxylic acid;
- 1-(2-(10,11-Dihydro-dibenzo[b,f]azepin-5-ylmethyl)-1-pentyl)-(3R)-piperidinecarboxylic acid;
- 30 acid;
- 1-(3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-(3R)-piperidinecarboxylic acid;
- 35 1-(3-(3-Trifluoromethyl-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-(3R)-piperidinecarboxylic acid;

- 1-(3-(3-Methyl-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-(3R)-piperidinecarboxylic acid;
- 5 1-(3-(3-Methoxy-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-(3R)-piperidinecarboxylic acid;
- 1-(3-(2-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-(3R)-piperidinecarboxylic acid;
- 10 2-(4-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-1-piperazinyl)-nicotinic acid;
- 1-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-(3R)-piperidinecarboxylic acid;
- 15 1-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-cyclopropylmethyl)-(3R)-piperidinecarboxylic acid;
- 20 1-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-cyclopentylmethyl)-(3R)-piperidinecarboxylic acid;
- 1-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-1-ethyl)-(3R)-piperidinecarboxylic acid;
- 25 (R)-1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-3-oxopropyl)-3-piperidinecarboxylic acid;
- (R)-1-(4-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-benzyl)-3-piperidinecarboxylic acid;
- 30 (R)-1-(4-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-butyn-1-yl)-3-piperidinecarboxylic acid
- (R)-1-((2R)-Methyl-3-(3-methyl-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-4-
- 35 piperidinecarboxylic acid;



- (R)-1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)1-methylpropyl)-3-piperidinecarboxylic acid;
- 5 (R)-1-(2-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-methyl-ethyl)-3-piperidinecarboxylic acid;
- (R)-1-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidine-carboxylic acid;
- 10 (R)-1-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)methyl)-3-piperidinecarboxylic acid;
- 1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methyl-1-propyl)-3-pyrrolidinylacetic acid;
- 15 2-(1-(3-(10,11-Dihydrodibenzo[b,f]azepin-5-yl)-(2R)-methylpropyl)-4-piperazinyl)-nicotinic acid;
- (R)-1-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)methyl)-1-pentyl)-3-piperidinecarboxylic acid;
- 20 2-(4-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-hydroxypropyl)piperazin-1-yl)nicotinic acid;
- 1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-methyl-3-oxo-propyl)-3-piperidinecarboxylic acid;
- 25 (R)-1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propionyl)-3-piperidinecarboxylic acid;
- 1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propionyl)-4-piperidinecarboxylic acid;
- 30 (R)-1-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-ylcarbonyl)-1-benzyl)-3-piperidinecarboxylic acid;
- (R)-1-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-ylmethyl)-benzyl)-3-piperidinecarboxylic acid;
- 35

- (R)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-3-oxo-1-propyl)-3-piperidinecarboxylic acid;
- 1-(3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-(2R)-methylpropyl)-4-piperidine-carboxylic acid;
- 1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-hydroxy-propyl)-4-piperidinecarboxylic acid;
- (R)-1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-hydroxypropyl)-3-piperidinecarboxylic acid;
- 1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-propoxypropyl)-4-piperidinecarboxylic acid;
- (R)-1-(2-(N-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-N-methylamino)ethyl)-3-piperidinecarboxylic acid,
- or a pharmaceutically acceptable salt thereof.
18. The use according to anyone of the claims 1-3 wherein in formula Ia  $R^1$ ,  $R^{1a}$ ,  $R^2$  and  $R^{2a}$  independently are hydrogen, halogen, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl,  $C_{1-6}$ -alkoxy or methylthio,  $-NR^7R^8$  or  $-SO_2NR^7R^8$  wherein  $R^7$  and  $R^8$  independently are hydrogen or  $C_{1-6}$ -alkyl; and
- Y is  $>\underline{CH}-O-$  or  $>\underline{CH}-S(O)_y$  wherein y is 0, 1 or 2, or  $-N(R^8)-$  wherein  $R^8$  is hydrogen or  $C_{1-6}$ -alkyl; and
- X is completion of an optional bond, ortho-phenylene,  $-O-$ ,  $-S-$ ,  $-C(R^7R^8)-$ ,  $-CH_2CH_2-$ ,  $-CH=CH-CH_2-$ ,  $-CH_2-CH=CH-$ ,  $-CH_2-(C=O)-$ ,  $-(C=O)-CH_2-$ ,  $-CH_2CH_2CH_2-$ ,  $-CH=CH-$ ,  $-N(R^8)-(C=O)-$ ,  $-(C=O)-N(R^8)-$ ,  $-O-CH_2-$ ,  $-CH_2-O-$ ,  $-OCH_2O-$ ,  $-CH_2OCH_2-$ ,  $-S-CH_2-$ ,  $-CH_2-S-$ ,  $-(CH_2)N(R^8)-$ ,  $-N(R^8)(CH_2)-$ ,  $-N(CH_3)SO_2-$ ,  $-SO_2N(CH_3)-$ ,  $-CH(R^9)CH_2-$ ,  $-CH_2CH(R^9)-$ ,  $-(C=O)-$ ,  $-N(R^8)-$  or  $-(S=O)-$  wherein  $R^7$  and  $R^8$  independently are hydrogen or  $C_{1-6}$ -alkyl; and wherein  $R^9$  is  $C_{1-6}$ -alkyl or phenyl; and
- p and q independently are 0 or 1; and
- r is 1, 2, 3 or 4; and
- Z is selected from




wherein  $g$  is 0, 1 or 2; and

- 5  $R^{11u}$  is hydrogen,  $C_{1-6}$ -alkyl,  $C_{1-6}$ -alkoxy or phenyl optionally substituted with halogen, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy; and
- $R^{12u}$  is  $-(CH_2)_hOH$  or  $-(CH_2)_jCOR^{17u}$  wherein  $h$  is 0, 1, 2, 3, 4, 5 or 6 and  $j$  is 0 or 1 and wherein  $R^{17u}$  is  $-OH$ ,  $-NHR^{20u}$  or  $C_{1-6}$ -alkoxy wherein  $R^{20u}$  is hydrogen or  $C_{1-6}$ -alkyl; and
- $R^{13u}$  is hydrogen, halogen, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy; and
- 10  $R^{14u}$  is hydrogen or  $C_{1-6}$ -alkyl; and

C is C<sub>1-6</sub>-alkylene, C<sub>2-6</sub>-alkenylene or C<sub>2-6</sub>-alkynylene; and

... is optionally a single bond or a double bond; and

R<sup>18u</sup> is selected from




5 wherein M<sub>1</sub> and M<sub>2</sub> independently are C or N; and

R<sup>19u</sup> is hydrogen, C<sub>1-6</sub>-alkyl, phenyl or benzyl; and

R<sup>15u</sup> is hydrogen, halogen, trifluoromethyl, nitro or cyano; and

R<sup>16u</sup> is hydrogen, halogen, trifluoromethyl, nitro, cyano, -(CH<sub>2</sub>)<sub>k</sub>COR<sup>17u</sup>, -(CH<sub>2</sub>)<sub>k</sub>OH or -(CH<sub>2</sub>)<sub>k</sub>SO<sub>2</sub>R<sup>17u</sup> wherein k is 0, 1 or 2; or

10 R<sup>16u</sup> is selected from



or a pharmaceutically acceptable salt thereof.

15 19. The use according to anyone of the claims 1-3 and 18 wherein the compound is selected from the following:

1-(2-(10,11-Dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-(3R)-piperidinecarboxylic acid;

20

1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-4-piperidinecarboxylic acid;

5 1-(2-(2-Methyl-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-4-piperidinecarboxylic acid;

1-(2-(2-Methyl-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

10 1-(2-(8-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

1-(2-(8-Methylthio-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

15 (R)-1-(2-(10,11-Dihydrodibenzo[b,f]oxepin-10-yloxy)ethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-ylsulfanyl)ethyl)-3-piperidinecarboxylic acid;

20 (R)-1-(11H-Dibenz[b,f][1,4]oxathiepin-11-ylmethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(2-Chloro-7-fluoro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)ethyl)-3-piperidinecarboxylic acid;

25 (R)-1-(2-(2,4-Dichloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)ethyl)-3-piperidinecarboxylic acid,


or a pharmaceutically acceptable salt thereof.

30

20. The use according to anyone of the claims 1-3 wherein in formula Ia  $R^1$ ,  $R^{1a}$ ,  $R^2$  and  $R^{2a}$  independently are hydrogen, halogen, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy; and

35 Y is  $\text{>N-CH}_2\text{-}$ ,  $\text{>CH-CH}_2\text{-}$  or  $\text{>C=CH-}$  wherein only the underscored atom participates in the ring system; and

X is ortho-phenylene, -O-, -S-, -C(R<sup>7</sup>R<sup>8</sup>)-, -CH<sub>2</sub>CH<sub>2</sub>-, -CH=CH-CH<sub>2</sub>-, -CH<sub>2</sub>-CH=CH-, -CH<sub>2</sub>-(C=O)-, -(C=O)-CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, -CH=CH-, -N(R<sup>8</sup>)-(C=O)-, -(C=O)-N(R<sup>8</sup>)-, -O-CH<sub>2</sub>-, -CH<sub>2</sub>-O-, -OCH<sub>2</sub>O-, -S-CH<sub>2</sub>-, -CH<sub>2</sub>-S-, -(CH<sub>2</sub>)N(R<sup>8</sup>)-, -N(R<sup>8</sup>)(CH<sub>2</sub>)-, -N(CH<sub>3</sub>)SO<sub>2</sub>-, -SO<sub>2</sub>N(CH<sub>3</sub>)-, -CH(R<sup>9</sup>)CH<sub>2</sub>-, -CH<sub>2</sub>CH(R<sup>9</sup>)-, -(C=O)-, -N(R<sup>8</sup>)- or -(S=O)- wherein R<sup>7</sup> and R<sup>8</sup> independently are hydrogen or C<sub>1-6</sub>-alkyl; and wherein R<sup>9</sup> is C<sub>1-6</sub>-alkyl or phenyl; and p and q are 0; and r is 1, 2 or 3; and Z is selected from



wherein R<sup>53</sup> is -(CH<sub>2</sub>)<sub>pp</sub>COOH wherein pp is 2, 3, 4, 5 or 6; or a pharmaceutically acceptable salt thereof.

21. The use according to anyone of the claims 1-3 and 20 wherein the compound is selected from the following:

3-(1-(3-(10,11-Dihydrodibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-3-yl)propionic acid;

3-(1-(3-(10,11-Dihydrodibenzo[b,f]azepin-5-yl)-1-propyl)piperidin-3-yl)propionic acid;

3-(1-(2-(10,11-Dihydrodibenzo[a,d]cyclohepten-5-ylidene)ethyl)piperidin-4-yl)propionic acid;

3-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

3-(1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)piperidin-4-yl)propionic acid;

3-(1-(3-(Thioxanthen-9-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

3-(1-(3-(Xanthen-9-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

3-(1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

- 4-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-4-yl)-butyric acid;
- 5 3-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-2-yl)-propionic acid;
- 3-(1-(3-(1-Bromo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-4-yl)propionic acid;
- 10 3-(1-(3-(2-Fluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-4-yl)propionic acid;
- 3-(1-(3-(2-Trifluoromethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-4-yl)propionic acid;
- 15 3-(1-(3-(2-Hydroxy-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-4-yl)propionic acid;
- 20 3-(1-(3-(2-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-4-yl)propionic acid;
- 3-(1-(3-(2-Methoxy-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-4-yl)propionic acid;
- 25 3-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-1-propyl)piperidin-4-yl)propionic acid;
- 3-(1-(3-(6,11-Dihydro-dibenz[b,e]thiepin-11-ylidene)-1-propyl)piperidin-4-yl)propionic acid;
- 30 3-(1-(3-(2-Fluoro-6,11-dihydro-dibenz[b,e]thiepin-11-ylidene)-1-propyl)piperidin-4-yl)-propionic acid;
- 4-(1-(3-(6,11-Dihydro-dibenz[b,e]thiepin-11-ylidene)-1-propyl)piperidin-4-yl)butyric acid;
- 35 3-(1-(3-(6,11-Dihydro-dibenz[b,e]thiepin-11-ylidene)-1-propyl)piperidin-3-yl)propionic acid;

3-(1-(3-(6,11-Dihydro-dibenz[b,e]thiepin-11-ylidene)-1-propyl)piperidin-2-yl)propionic acid;

5 3-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)pyrrolidin-3-yl)-  
propionic acid;

4-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)pyrrolidin-3-yl)-  
butyric acid;

10 3-(1-(3-(6,11-Dihydro-dibenz[b,e]thiepin-11-ylidene)-1-propyl)pyrrolidin-3-yl)propionic acid;

3-(1-(3-(10H-Anthracen-9-ylidene)-1-propyl)pyrrolidin-3-yl)propionic acid;

15 3-(1-(3-(Dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)pyrrolidin-3-yl)propionic acid;

3-(1-(3-(10H-Anthracen-9-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

3-(1-(3-(Dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)piperidin-4-yl)propionic acid;

20 5-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-1-propyl)piperidin-4-yl)pentanoic  
acid;

5-(1-(3-(6,11-Dihydro-dibenz[b,e]thiepin-11-ylidene)-1-propyl)piperidin-4-yl)pentanoic acid;

25 5-(1-(3-(Thioxanthen-9-ylidene)-1-propyl)piperidin-4-yl)pentanoic acid;

5-(1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)piperidin-4-yl)pentanoic acid,

or a pharmaceutically acceptable salt thereof.


30

22. The use according to anyone of the claims 1-3 wherein in formula Ia  
R<sup>1</sup>, R<sup>1a</sup>, R<sup>2</sup> and R<sup>2a</sup> independently are hydrogen, halogen, trifluoromethyl, hydroxy, C<sub>1-6</sub>-alkyl  
or C<sub>1-6</sub>-alkoxy; and

Y is N-CH<sub>2</sub>- , CH-CH<sub>2</sub>- , C=CH- or CH-O- wherein only the underscored atom  
35 participates in the ring system; and



- X is ortho-phenylene, -O-, -S-, -C(R<sup>7</sup>R<sup>8</sup>)-, -CH<sub>2</sub>CH<sub>2</sub>-, -CH=CH-CH<sub>2</sub>-, -CH<sub>2</sub>-CH=CH-, -CH<sub>2</sub>-(C=O)-, -(C=O)-CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, -CH=CH-, -N(R<sup>8</sup>)-(C=O)-, -(C=O)-N(R<sup>8</sup>)-, -O-CH<sub>2</sub>-, -CH<sub>2</sub>-O-, -OCH<sub>2</sub>O-, -S-CH<sub>2</sub>-, -CH<sub>2</sub>-S-, -(CH<sub>2</sub>)N(R<sup>8</sup>)-, -N(R<sup>8</sup>)(CH<sub>2</sub>)-, -N(CH<sub>3</sub>)SO<sub>2</sub>-, -SO<sub>2</sub>N(CH<sub>3</sub>)-, -CH(R<sup>9</sup>)CH<sub>2</sub>-, -CH<sub>2</sub>CH(R<sup>9</sup>)-, -(C=O)-, -N(R<sup>8</sup>)- or -(S=O)- wherein R<sup>7</sup> and R<sup>8</sup> independently are hydrogen or C<sub>1-6</sub>-alkyl; and wherein R<sup>9</sup> is C<sub>1-6</sub>-alkyl or phenyl; and
- p and q are 0; and
- r is 1, 2 or 3; and
- Z is




- wherein tt and t independently are 0, 1 or 2; and
- R<sup>63</sup> is H, C<sub>1-6</sub>-alkyl or optionally substituted benzyl;
- R<sup>64</sup> and R<sup>65</sup> independently are H, C<sub>1-8</sub>-alkyl, C<sub>3-7</sub>-cycloalkyl, phenyl, thienyl, benzyl, or R<sup>64</sup> and R<sup>65</sup> together with the C-atom they are attached to form a 3 - 8 membered carbocyclic ring;
- and
- R<sup>66</sup> is H or C<sub>1-6</sub>-alkyl; or
- a pharmaceutically acceptable salt thereof.

23. The use according to anyone of the claims 1-3 and 22 wherein the compound is selected from the following:

- 1-(2-(10,11-Dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-(3R)-piperidinecarboxylic acid;
- 1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;
- 1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-4-piperidinecarboxylic acid;
- 1-(2-(2-Methyl-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-4-piperidinecarboxylic acid;

- 1-(2-(2-Methyl-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;
- 5 1-(2-(8-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;
- 1-(2-(8-Methylthio-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;
- 10 (R)-1-(2-(10,11-Dihydrodibenzo[b,f]oxepin-10-yloxy)ethyl)-3-piperidinecarboxylic acid;
- (R)-1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-ylsulfanyl)ethyl)-3-piperidinecarboxylic acid;
- 15 (R)-1-(11H-Dibenz[b,f][1,4]oxathiepin-11-ylmethyl)-3-piperidinecarboxylic acid;
- (R)-1-(2-(2-Chloro-7-fluoro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)ethyl)-3-piperidinecarboxylic acid;
- 20 (R)-1-(2-(2,4-Dichloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)ethyl)-3-piperidinecarboxylic acid,
- or a pharmaceutically acceptable salt thereof.
- 25 24. The use according to anyone of the claims 1-3 wherein in formula Ia  $R^1$ ,  $R^{1a}$ ,  $R^2$  and  $R^{2a}$  independently are hydrogen, halogen, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy; and
- Y is  $>\underline{N}$ -CH<sub>2</sub>-,  $>\underline{CH}$ -CH<sub>2</sub>- or  $>\underline{C}$ =CH- wherein only the underscored atom participates in the ring system; and
- 30 X is ortho-phenylene, -O-, -S-, -C( $R^7$  $R^8$ )-, -CH<sub>2</sub>CH<sub>2</sub>-, -CH=CH-CH<sub>2</sub>-, -CH<sub>2</sub>-CH=CH-, -CH<sub>2</sub>-(C=O)-, -(C=O)-CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, -CH=CH-, -N( $R^8$ )-(C=O)-, -(C=O)-N( $R^8$ )-, -O-CH<sub>2</sub>-, -CH<sub>2</sub>-O-, -OCH<sub>2</sub>O-, -S-CH<sub>2</sub>-, -CH<sub>2</sub>-S-, -(CH<sub>2</sub>)N( $R^8$ )-, -N( $R^8$ )(CH<sub>2</sub>)-, -N(CH<sub>3</sub>)SO<sub>2</sub>-, -SO<sub>2</sub>N(CH<sub>3</sub>)-, -CH( $R^9$ )CH<sub>2</sub>-, -CH<sub>2</sub>CH( $R^9$ )-, -(C=O)-, -N( $R^8$ )- or -(S=O)- wherein  $R^7$  and  $R^8$  independently are hydrogen or  $C_{1-6}$ -alkyl; and wherein  $R^9$  is  $C_{1-6}$ -alkyl or phenyl; and
- 35 p and q are 0; and
- r is 0, 1 or 2; and

Z is selected from



wherein D is  $-\text{CH}_2-$ ,  $-\text{O}-$ ,  $-\text{S}-$  or  $-\text{N}(\text{R}^7)-$  wherein  $\text{R}^7$  is H or  $\text{C}_{1-6}$ -alkyl; and  $\text{R}^{3m}$  is  $-(\text{CH}_2)_{mm}\text{OH}$  or  $-(\text{CH}_2)_{mp}\text{COR}^4$  wherein mm and mp are 1, 2, 3 or 4 and  $\text{R}^4$  is OH,  $\text{NH}_2$ ,  $\text{NHOH}$  or  $\text{C}_{1-6}$ -alkoxy; or a pharmaceutically acceptable salt thereof.

25. The use according to anyone of the claims 1-3 and 24 wherein the compound is selected from the following:

3-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-ylmethyl)-pyrrolidin-1-yl)-propionic acid;

(2-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-ylmethyl)-morpholin-4-yl)-acetic acid;

(3-(10,11-Dihydro-5H-dibenz[(b,f)azepin-5-ylmethyl)-1-piperidyl)acetic acid,

or a pharmaceutically acceptable salt thereof.

26. The use according to anyone of the claims 1-3 wherein in formula Ia

$\text{R}^1$ ,  $\text{R}^{1a}$ ,  $\text{R}^2$  and  $\text{R}^{2a}$  independently are hydrogen, halogen, cyano, trifluoromethyl, methylthio, hydroxy,  $\text{C}_{1-6}$ -alkyl or  $\text{C}_{1-6}$ -alkoxy; and


$\text{Y}$  is  $>\underline{\text{N}}-$ ,  $>\underline{\text{CH}}-$ ,  $>\underline{\text{N}}-(\text{C}=\text{O})-$  or  $>\underline{\text{C}}=\text{C}(\text{R}^8)-$ , wherein only the underscored atom participates in the ring system and  $\text{R}^8$  is hydrogen or  $\text{C}_{1-6}$ -alkyl; and

$\text{X}$  is ortho-phenylene,  $-\text{O}-$ ,  $-\text{S}-$ ,  $-\text{C}(\text{R}^7\text{R}^8)-$ ,  $-\text{CH}_2\text{CH}_2-$ ,  $-\text{CH}=\text{CH}-\text{CH}_2-$ ,  $-\text{CH}_2-\text{CH}=\text{CH}-$ ,  $-\text{CH}_2-$

$(\text{C}=\text{O})-$ ,  $-(\text{C}=\text{O})-\text{CH}_2-$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2-$ ,  $-\text{CH}=\text{CH}-$ ,  $-\text{N}(\text{R}^8)-(\text{C}=\text{O})-$ ,  $-(\text{C}=\text{O})-\text{N}(\text{R}^8)-$ ,  $-\text{O}-\text{CH}_2-$ ,  $-\text{CH}_2-\text{O}-$ ,  $-\text{OCH}_2\text{O}-$ ,  $-\text{CH}_2\text{OCH}_2-$ ,  $-\text{S}-\text{CH}_2-$ ,  $-\text{CH}_2-\text{S}-$ ,  $-(\text{CH}_2)\text{N}(\text{R}^8)-$ ,  $-\text{N}(\text{R}^8)(\text{CH}_2)-$ ,  $-\text{N}(\text{CH}_3)\text{SO}_2-$ , -

$\text{SO}_2\text{N}(\text{CH}_3)-$ ,  $-\text{CH}(\text{R}^9)\text{CH}_2-$ ,  $-\text{CH}_2\text{CH}(\text{R}^9)-$ ,  $-(\text{C}=\text{O})-$ ,  $-\text{N}(\text{R}^8)-$  or  $-(\text{S}=\text{O})-$  wherein  $\text{R}^7$  and  $\text{R}^8$  independently are hydrogen or  $\text{C}_{1-6}$ -alkyl; and wherein  $\text{R}^9$  is  $\text{C}_{1-6}$ -alkyl or phenyl; and  $p$  and  $q$  are 0; and  $r$  is 0, 1, 2, 3 or 4; and


5 Z is



wherein  $b$  is 0, 1, 2, 3 or 4; and

B is  $-\text{CH}=\text{CR}^{49}-$ ,  $-\text{CR}^{49}=\text{CH}-$ ,  $-\text{C}\equiv\text{C}-$ ,  $-(\text{C}=\text{O})-$ ,  $-(\text{C}=\text{CH}_2)-$ ,  $-(\text{CR}^{49}\text{R}^{40})-$ ,  $-\text{CH}(\text{OR}^{41})-$ ,  $-\text{CH}(\text{NHR}^{41})-$ , phenylene,  $\text{C}_{3-7}$ -cycloalkylene or the completion of a bond, wherein  $\text{R}^{49}$  and  $\text{R}^{40}$  independently are hydrogen,  $\text{C}_{1-6}$ -unbranched alkyl,  $\text{C}_{3-6}$ -branched alkyl or  $\text{C}_{3-7}$ -cycloalkyl and wherein  $\text{R}^{41}$  is hydrogen or  $\text{C}_{1-6}$ -alkyl; and

10 U is



wherein  $\text{R}^{42}$  is hydrogen,  $-(\text{CH}_2)_c\text{OH}$  or  $-(\text{CH}_2)_d\text{COR}^{47}$  wherein  $c$  is 0, 1, 2, 3, 4, 5 or 6 and  $d$  is 0 or 1 and wherein  $\text{R}^{47}$  is  $-\text{OH}$ ,  $-\text{NHR}^{44}$  or  $\text{C}_{1-6}$ -alkoxy wherein  $\text{R}^{44}$  is hydrogen or  $\text{C}_{1-6}$ -alkyl; and

$\text{R}^{43}$  is cyano,  $-\text{NR}^{45}\text{R}^{46}$ ,  $-\text{NR}^{45}-\text{V}$  or  $-(\text{CHR}^{48})_e-\text{V}$  wherein  $\text{R}^{45}$  and  $\text{R}^{46}$  independently are hydrogen or  $\text{C}_{1-6}$ -alkyl and wherein  $e$  is 0, 1, 2, 3, 4, 5 or 6 and wherein  $\text{R}^{48}$  is hydrogen, halogen, cyano, trifluoromethyl, hydroxy,  $\text{C}_{1-6}$ -alkyl,  $\text{C}_{1-6}$ -alkoxy,  $-\text{NR}^{45}\text{R}^{46}$  or  $-\text{COOH}$ , and

20 wherein V is  $\text{C}_{3-8}$ -cycloalkyl, aryl or heteroaryl, which rings may optionally be substituted with one or more halogen, cyano, trifluoromethyl, hydroxy, methylthio,  $\text{C}_{1-6}$ -alkyl or  $\text{C}_{1-6}$ -alkoxy; or a pharmaceutically acceptable salt thereof.


27. The use according to anyone of the claims 1-3 and 26 wherein the compound is

25 selected from the following:

1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-phenyl-4-piperidinecarboxylic acid;

30 4-(4-Chlorophenyl)-1-(3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-piperidinecarboxylic acid;

- 4-(4-Methylphenyl)-1-(3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-piperidinecarboxylic acid;
- 5 1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-anilino-4-piperidinecarboxamide;
- 2-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-piperidyl)-2-phenylacetonitrile;
- 10 2-(1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-piperidiny)-2-phenylacetic acid;
- 1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-4-cyano-4-piperidinecarboxylic acid,
- 15 or a pharmaceutically acceptable salt thereof.
28. The use according to anyone of the claims 1-3 wherein in formula Ib
- 20  $R^{1b}$  and  $R^{2b}$  independently are hydrogen, halogen, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy; and
- $R^{3b}$  is hydrogen or  $C_{1-3}$ -alkyl; and
- $A_b$  is  $C_{1-3}$ -alkylene; and
- $Y_b$  is  $>\underline{C}H-CH_2-$ ,  $>\underline{C}=CH-$ ,  $>\underline{C}H-O-$ ,  $>\underline{C}=N-$ ,  $>\underline{N}-CH_2-$  wherein only the underscored atom
- 25 participates in the ring system; and
- $Z_b$  is selected from



- 5 wherein  $nb$  is 1 or 2; and  
 $R^{11b}$  is hydrogen or  $C_{1-6}$ -alkyl; and  
 $R^{12b}$  is hydrogen,  $C_{1-6}$ -alkyl,  $C_{1-6}$ -alkoxy or phenyl optionally substituted with halogen, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy; and  
 $R^{13b}$  is hydrogen, halogen, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy; and  
10  $R^{14b}$  is  $-(CH_2)_{mb}OH$  or  $-(CH_2)_{mb}COR^{15b}$  wherein  $mb$  is 0, 1, 2, 3, 4, 5 or 6 and  $tb$  is 0 or 1 and wherein  $R^{15b}$  is  $-OH$ ,  $NH_2$ ,  $-NHOH$  or  $C_{1-6}$ -alkoxy; and

$R^{16b}$  is  $C_{1-6}$ -alkyl or  $-B_b-COR^{15b}$ , wherein  $B_b$  is  $C_{1-6}$ -alkylene,  $C_{2-6}$ -alkenylene or  $C_{2-6}$ -alkynylene and  $R^{15b}$  is the same as above; and  
 is optionally a single bond or a double bond; or  
 a pharmaceutically acceptable salt thereof.

5

29. The use according to anyone of the claims 1-3 and 28 wherein the compound is selected from the following:

10

1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-piperidinecarboxylic acid ethyl ester;

15

1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-4-piperidinecarboxylic acid;

(R)-1-(3-(2,10-Dichloro-12H-dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

20

1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-pyrrolidineacetic acid;

1-(3-(2,10-Dichloro-12H-dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-pyrrolidineacetic acid;

25

(R)-1-(2-(12H-Dibenzo[d,g][1,3]dioxocin-12-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(2,10-Dichloro-12H-dibenzo[d,g][1,3]dioxocin-12-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

30

(R)-1-(3-(2-Chloro-12H-dibenzo[d,g][1,3,6]dioxazocin-12-yl)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(12H-Dibenzo[d,g][1,3,6]dioxazocin-12-yl)-1-propyl)-4-piperidinecarboxylic acid;

35

2-Chloro-12-(3-dimethylamino)propylidene-12H-dibenzo[d,g][1,3]dioxocine;

- 2,10-Dichloro-12-(2-dimethylamino)ethoxy-12H-dibenzo[d,g][1,3]dioxocine;
- 2,10-Dichloro-12-(3-dimethylamino)propyl-12H-dibenzo[d,g][1,3]dioxocine;
- 5 2,10-Dichloro-12-(3-dimethylamino-1-methyl)ethoxy-12H-dibenzo[d,g][1,3]dioxocine;
- 3-Chloro-12-(2-dimethylaminopropylidene)-12H-dibenzo[d,g][1,3]dioxocine;
- 10 3-Chloro-12-(3-dimethylamino)propylidene-12H-dibenzo[d,g][1,3]dioxocine;
- 3-Chloro-12-(3-dimethylamino-1-methylpropylidene)-12H-dibenzo[d,g][1,3]dioxocine;
- 2-Fluoro-12-(3-dimethylamino)propylidene-12H-dibenzo[d,g][1,3]dioxocine;
- 15 2-Methyl-12-(3-(4-methyl-1-piperazinyl)propylidene)-12H-dibenzo[d,g][1,3]dioxocine;
- 2-Chloro-12-(3-(4-methyl-1-piperazinyl)propylidene)-12H-dibenzo[d,g][1,3]dioxocine;
- 20 3-Chloro-12-(3-(4-methyl-1-piperazinyl)propylidene)-12H-dibenzo[d,g][1,3]dioxocine;
- 1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)propyl)-3-piperidinecarboxylic acid ethyl ester;
- 25 1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)propyl)-3-piperidinecarboxylic acid,
- or a pharmaceutically acceptable salt thereof.
30. The use according to anyone of the claims 1-3 wherein in formula Ic
- 30  $R^{1c}$  and  $R^{2c}$  independently are hydrogen, halogen, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy; and
- $X_c$  is ortho-phenylene, -O-, -S-,  $-C(R^{6c}R^{7c})-$ ,  $-CH_2CH_2-$ ,  $-CH=CH-CH_2-$ ,  $-CH_2-CH=CH-$ ,  $-CH_2-$ ,  $-(C=O)-$ ,  $-(C=O)-CH_2-$ ,  $-CH_2CH_2CH_2-$ ,  $-CH=CH-$ ,  $-N(R^{8c})-(C=O)-$ ,  $-(C=O)-N(R^{8c})-$ ,  $-O-CH_2-$ ,  $-CH_2-$ ,  $-O-$ ,  $-OCH_2O-$ ,  $-S-CH_2-$ ,  $-CH_2-S-$ ,  $-(CH_2)N(R^{8c})-$ ,  $-N(R^{8c})(CH_2)-$ ,  $-N(CH_3)SO_2-$ ,  $-SO_2N(CH_3)-$ ,  $-CH(R^{10c})CH_2-$ ,  $-CH_2CH(R^{10c})-$ ,  $-(C=O)-$ ,  $-N(R^{9c})-$  or  $-(S=O)-$  wherein  $R^{6c}$ ,  $R^{7c}$ ,  $R^{8c}$  and  $R^{9c}$
- 35 independently are hydrogen or  $C_{1-6}$ -alkyl, and wherein  $R^{10c}$  is  $C_{1-6}$ -alkyl or phenyl; and




$Y_c$  is C or N; and

... is optionally a single bond or a double bond, and ... is a single bond when  $Y_c$  is N; and

$m_c$  is 1, 2, 3, 4, 5 or 6; and

$Z_c$  is  $-\text{COOR}^{3c}$  or



5

wherein  $R^{3c}$  is H or  $C_{1-6}$ -alkyl; or

a pharmaceutically acceptable salt thereof.

31. The use according to anyone of the claims 1-3 and 30 wherein the compound is  
10 selected from the following:

1-(2-(10,11-Dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-(3R)-piperidinecarboxylic  
acid;

15 1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidine-  
carboxylic acid;

1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-4-piperidine-  
carboxylic acid;

20

1-(2-(2-Methyl-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-4-piperidine-  
carboxylic acid;

25

1-(2-(2-Methyl-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidine-  
carboxylic acid;

1-(2-(8-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidine-  
carboxylic acid;

30

1-(2-(8-Methylthio-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)-1-ethyl)-3-piperidine-  
carboxylic acid;

(R)-1-(2-(10,11-Dihydrodibenzo[b,f]oxepin-10-yloxy)ethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(2-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-ylsulfanyl)ethyl)-3-piperidinecarboxylic acid;

(R)-1-(11H-Dibenz[b,f][1,4]oxathiepin-11-ylmethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(2-Chloro-7-fluoro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)ethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(2,4-Dichloro-10,11-dihydrodibenzo[b,f]thiepin-10-yloxy)ethyl)-3-piperidinecarboxylic acid,

or a pharmaceutically acceptable salt thereof.


32. The use according to anyone of the claims 1-3 wherein in formula Id

$R^{1d}$  and  $R^{2d}$  independently are hydrogen, halogen, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy; and

$X_d$  is -O-, -S- or -S(=O)-; and

$rd$  is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; and

$Z_d$  is selected from



wherein  $R^{3d}$  is  $-(CH_2)_{md}OH$  or  $-(CH_2)_{pd}COR^{4d}$  wherein  $md$  and  $pd$  independently are 0, 1, 2, 3 or 4 and  $R^{4d}$  is OH,  $NH_2$ ,  $NHOH$  or  $C_{1-6}$ -alkoxy, or a pharmaceutically acceptable salt thereof.

33. The use according to anyone of the claims 1-3 and 32 wherein the compound is selected from the following:

4-(1,3,4,14b-Tetrahydro-2H-dibenzo[b,f]pyrazino[1,2-d][1,4]oxazepin-2-yl)-butanoic acid;

4-(1,3,4,14b-Tetrahydro-2H-dibenzo[b,f]pyrazino[1,2-d][1,4]thiazepin-2-yl)-butanoic acid,

or a pharmaceutically acceptable salt thereof.

- 15